Skip to main content
Galecto, Inc. logo

Galecto, Inc. — Investor Relations & Filings

Ticker · GLTO ISIN · US36322Q1076 US Manufacturing
Open in API
Filings indexed 310 across all filing types
Latest filing 2026-05-04 Board/Management Inform…
Country US United States of America
Listing US GLTO

About Galecto, Inc.

https://galecto.com/

Galecto, Inc. is a clinical-stage biotechnology company that develops novel small molecule therapeutics for cancer and severe liver diseases. The company leverages its expertise in galectin biology to create product candidates that modulate central disease pathways. Its pipeline focuses on inhibitors of key proteins such as galectin-3 and LOXL2, which are implicated in fibrosis and cancer progression. In October 2024, Galecto expanded its oncology portfolio by acquiring GB3226, a novel dual ENL-YEATS and FLT3 inhibitor for the treatment of multiple genetic subsets of acute myeloid leukemia (AML). The company's research also targets other cancers, including melanoma, head and neck squamous cell carcinoma (HNSCC), and hepatocellular carcinoma (HCC). Galecto's mission is to develop safe and effective treatments that significantly improve patient quality of life.

Recent filings

Filing Released Lang Actions
8-K - Damora Therapeutics, Inc. (0001800315) (Filer)
Board/Management Information Classification · 90% confidence The document is a Form 8-K current report filed under Item 5.02 covering the departure and appointment of senior officers (CFO), which constitutes a management change announcement. This falls under Board/Management Information.
2026-05-04 English
8-K - Damora Therapeutics, Inc. (0001800315) (Filer)
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated April 17, 2026, by Damora Therapeutics, Inc. The key content is the announcement of a change in the company's independent registered public accounting firm: dismissal of EY Denmark and appointment of EY US. It details the circumstances around the dismissal and appointment, including references to audit reports and disagreements, but does not contain actual financial statements or detailed financial data. The document is a current report notifying a significant change in the company's auditor, which falls under management or board-related announcements. According to the filing definitions, announcements of changes in the company's board of directors or senior management, including changes in auditors, are classified as Board/Management Information (MANG). The document is not an audit report itself, nor an annual or interim report, but a regulatory filing announcing a management-related change. Therefore, the appropriate classification is MANG with high confidence.
2026-04-20 English
4 - Damora Therapeutics, Inc. (0001800315) (Issuer)
Director's Dealing
2026-03-25 English
4 - Damora Therapeutics, Inc. (0001800315) (Issuer)
Director's Dealing
2026-03-25 English
4 - Damora Therapeutics, Inc. (0001800315) (Issuer)
Director's Dealing
2026-03-25 English
4 - Damora Therapeutics, Inc. (0001800315) (Issuer)
Director's Dealing
2026-03-25 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.